recombinant thyroid-stimulating hormone

Phase 1Biologic

recombinant thyroid-stimulating hormone is one of 3 biologic programs targeting Chronic Lung Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lung DiseaseActive, not recruiting

Chronic Lung DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Chronic Lung Disease

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Pulmicort

SSalix

Approved

1 3

recombinant thyroid-stimulating hormone

UUniversity College, London

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer

Unknown status·UUniversity College, London·Phase 3·NCT00415233·438 enrolled

Chronic Lung Disease1 trial

Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease

Active, not recruiting·UUniversity College, London·Phase 1·NCT05898633·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for recombinant thyroid-stimulating hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant thyroid-stimulating hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant thyroid-stimulating hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity College, London

recombinant thyroid-stimulating hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Cancer1 trial

Chronic Lung Disease1 trial

References

Drug Info

Quick Facts

Related News